Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asher Chanan-Khan

Showing results (21-30 of 101) with videos related to

Pageof 11
Sort By:
Oncology|July 26, 2014
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myelomaMiriam Y Kim, Richard Sposto, Abhisek Swaika, et al.
Journal of Primary Care & Community Health|March 2, 2021
A Panel Evaluation of the Changes in the General Public's Social-Media-Following of United States' Public Health Departments during COVID-19 PandemicAreej Khokhar, Aaron Spaulding, Zuhair Niazi, et al.
Haematologica|May 15, 2003
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndromeAsher Chanan-Khan, Beata Holkova, Mary Ann Perle, et al.
Journal of Managed Care & Specialty Pharmacy|April 10, 2025
Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemiaAsher Chanan-Khan, Kirollos Hanna, Mei Xue, et al.
Future Oncology (London, England)|January 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemiaMazyar Shadman, Asher Chanan-Khan, David Campbell, et al.
SAGE Open Medical Case Reports|February 8, 2019
Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemiaSharad Khurana, Salman Ahmed, Victoria R Alegria, et al.
Cancer|December 6, 2002
A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcomaZale P Bernstein, Asher Chanan-Khan, Kena C Miller, et al.
Leukemia & Lymphoma|June 20, 2020
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemiaVijay Sagar Madamsetty, Aneel Paulus, Sharoon Akhtar, et al.
Cancer Immunology, Immunotherapy : CII|April 28, 2010
Antitumor cytotoxic T-cell response induced by a survivin peptide mimicMichael J Ciesielski, Manmeet S Ahluwalia, Stephan A Munich, et al.
HIV Clinical Trials|July 13, 2004
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAARTSridhar Srinivasan, Kenichi Takeshita, Beata Holkova, et al.
Pageof 11

Showing results (21-30 of 101) with videos related to

Sort By:
Pageof 11
Oncology|July 26, 2014
Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myelomaMiriam Y Kim, Richard Sposto, Abhisek Swaika, et al.
Journal of Primary Care & Community Health|March 2, 2021
A Panel Evaluation of the Changes in the General Public's Social-Media-Following of United States' Public Health Departments during COVID-19 PandemicAreej Khokhar, Aaron Spaulding, Zuhair Niazi, et al.
Haematologica|May 15, 2003
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndromeAsher Chanan-Khan, Beata Holkova, Mary Ann Perle, et al.
Journal of Managed Care & Specialty Pharmacy|April 10, 2025
Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemiaAsher Chanan-Khan, Kirollos Hanna, Mei Xue, et al.
Future Oncology (London, England)|January 31, 2026
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemiaMazyar Shadman, Asher Chanan-Khan, David Campbell, et al.
SAGE Open Medical Case Reports|February 8, 2019
Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemiaSharad Khurana, Salman Ahmed, Victoria R Alegria, et al.
Cancer|December 6, 2002
A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcomaZale P Bernstein, Asher Chanan-Khan, Kena C Miller, et al.
Leukemia & Lymphoma|June 20, 2020
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemiaVijay Sagar Madamsetty, Aneel Paulus, Sharoon Akhtar, et al.
Cancer Immunology, Immunotherapy : CII|April 28, 2010
Antitumor cytotoxic T-cell response induced by a survivin peptide mimicMichael J Ciesielski, Manmeet S Ahluwalia, Stephan A Munich, et al.
HIV Clinical Trials|July 13, 2004
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAARTSridhar Srinivasan, Kenichi Takeshita, Beata Holkova, et al.
Pageof 11